Ajinomoto Cambrooke, Inc.
Neelima Shandilya, PhD, currently serves as a Senior Scientist in Product Development at Ajinomoto Cambrooke, Inc. since March 2023. Prior experience includes roles as a Formulation Scientist at Blueshift Nutrition from January 2021 to February 2023, and as a Food Scientist at Chew from April 2018 to January 2021. Additional positions held include Food Science Consultant at Ocean Spray Cranberries and Welch's, and Food Scientist at Truweight. Neelima's academic background includes a Doctor of Philosophy in Food Science and Technology from the Indian Institute of Technology, Kharagpur, along with an MSc in Food Processing Technology from Tezpur University and a Bachelor of Science with Honors in Food Science and Technology from Delhi University.
This person is not in any teams
This person is not in any offices
Ajinomoto Cambrooke, Inc.
Ajinomoto Cambrooke, Inc. formerly Cambrooke Therapeutics, Inc. (expansion of Cambrooke Foods) was founded in 2000 by Lynn and David Paolella, the parents of two children diagnosed with a rare disease called phenylketonuria (PKU). PKU is one of the few genetic diseases, which is managed almost entirely with nutritional intervention. The Paolellas’ goal in forming Cambrooke was simple - to develop improved nutritional therapeutic options for those with serious medical disorders. Today, Cambrooke produces medical formulas and foods for the management of a variety of medical conditions and we are continually innovating new nutritional options targeted at a wide array of diseases. Ajinomoto Cambrooke, Inc. - Leaders in Therapeutic Medical Nutrition. Cambrooke was the first medical foods company to launch a natural intact protein for the dietary management of phenylketonuria called Glytactin™ (modified glycomacropeptide). Cambrooke collaborates with academia and industry partners to transform early phase development projects in therapeutic nutrition into viable commercial products. Cambrooke employs scientific experts in the development, manufacturing and commercialization of nutritional therapeutics for patients with rare diseases. Cambrooke’s products are supported by clinical evidence for the nutritional management of medical needs before they are selected for commercialization. Cambrooke believes that both large and small patient populations are important when it comes to complex nutritional requirements.